Jan 23, 2024
BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics
Jan 07, 2021
BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson's Disease
Sep 25, 2019
BlueRock Therapeutics to Present at 2019 Cell & Gene Meeting on the Mesa
Mar 05, 2019
BlueRock Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference
Jan 16, 2019
BlueRock Therapeutics Establishes Key Partnerships with Leading Experts in Autoimmune Disease
Dec 06, 2018
BlueRock Therapeutics Strengthens Collaboration with the McEwen Stem Cell Institute
Nov 26, 2018
BlueRock Therapeutics Appoints Min Wang, J.D., Ph.D., as Chief Legal and Administrative Officer
Oct 01, 2018
BlueRock Therapeutics to Present at 2018 Cell & Gene Meeting on the Mesa
Apr 17, 2018
BlueRock Therapeutics Establishes R&D Site in New York City and Formalizes Collaboration with Memorial Sloan Kettering Cancer Center
Dec 01, 2017
BlueRock Therapeutics Announces Appointment of Derek Hei, Ph.D. as Senior Vice President, Manufacturing, Quality and Regulatory
Oct 26, 2017
BlueRock Therapeutics Establishes Corporate Headquarters in Cambridge, Massachusetts and Bolsters Team to Support Rapid Growth and Development
Oct 03, 2017
BlueRock Therapeutics and Universal Cells Enter Collaboration and License Agreement to Generate Gene-Edited iPS Cell Lines
Jun 27, 2017
BlueRock Therapeutics Announces Key Members of Executive Team